Mechanism of immune response during immunotherapy

Monica C. Panelli, Dirk Nagorsen, Ena Wang, Vladia Monsurro, Ping Jin, Zavaglia Katia, Kina Smith, Yvonne Ngalame, Francesco M. Marincola

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Tumor immunology embraces an extensive array of biological phenomena that include interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the center stage because they can be easily demonstrated to specifically recognize autologous cancer cells. However, their role is limited and other components of the immune response are likely necessary for the completion of cancer rejection. Metastatic melanoma and renal cell carcinoma (RCC) are malignancies strongly predisposed to regress in response to the systemic administration of high-dose interleukin (IL)-2. Several clinical Studies in extensive cohorts of patients have shown that this treatment can induce complete or partial clinical regressions of metastatic disease in 15 to 20% of patients who receive this treatment. Although IL-2 has direct pluri-potent effects on cells with immune and inflammatory function, it remains unexplained which cell subset is implicated in mediating tumor regression. In a quest to characterize the mechanism of action of IL-2 during the course of immunotherapy, we have investigated the early changes in transcriptional profiles of circulating mononuclear cells and microenvironment of melanoma metastases following high dose IL-2 administration (720,000 IU/kg) by serial sampling of blood cells and tumors in the form of fine needle aspirate (FNA). Furthermore, studies are currently on-going to characterize the proteomic profiling of RCC patients undergoing the same treatment using protein arrays (manuscript in preparation). The predominant activation of genes related to inflammation and activation of mononuclear phagocytes lead us to further characterize this cell subset in the context of stimulation with a panel of soluble factors potentially present in the circulation and tumor microenvironment.

Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalYonsei Medical Journal
Volume45
Issue numberSUPPL.
Publication statusPublished - 30 Jun 2004
Externally publishedYes

Fingerprint

Immunotherapy
Interleukin-2
Neoplasms
Renal Cell Carcinoma
Melanoma
Biological Phenomena
Cellular Microenvironment
Protein Array Analysis
Tumor Microenvironment
Manuscripts
Adaptive Immunity
Phagocytes
Allergy and Immunology
Innate Immunity
Proteomics
Transcriptional Activation
Needles
Blood Cells
Therapeutics
Neoplasm Metastasis

Keywords

  • Immunization
  • Immunotherapy
  • Interleukin-2
  • Melanoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Panelli, M. C., Nagorsen, D., Wang, E., Monsurro, V., Jin, P., Katia, Z., ... Marincola, F. M. (2004). Mechanism of immune response during immunotherapy. Yonsei Medical Journal, 45(SUPPL.), 15-17.

Mechanism of immune response during immunotherapy. / Panelli, Monica C.; Nagorsen, Dirk; Wang, Ena; Monsurro, Vladia; Jin, Ping; Katia, Zavaglia; Smith, Kina; Ngalame, Yvonne; Marincola, Francesco M.

In: Yonsei Medical Journal, Vol. 45, No. SUPPL., 30.06.2004, p. 15-17.

Research output: Contribution to journalReview article

Panelli, MC, Nagorsen, D, Wang, E, Monsurro, V, Jin, P, Katia, Z, Smith, K, Ngalame, Y & Marincola, FM 2004, 'Mechanism of immune response during immunotherapy', Yonsei Medical Journal, vol. 45, no. SUPPL., pp. 15-17.
Panelli MC, Nagorsen D, Wang E, Monsurro V, Jin P, Katia Z et al. Mechanism of immune response during immunotherapy. Yonsei Medical Journal. 2004 Jun 30;45(SUPPL.):15-17.
Panelli, Monica C. ; Nagorsen, Dirk ; Wang, Ena ; Monsurro, Vladia ; Jin, Ping ; Katia, Zavaglia ; Smith, Kina ; Ngalame, Yvonne ; Marincola, Francesco M. / Mechanism of immune response during immunotherapy. In: Yonsei Medical Journal. 2004 ; Vol. 45, No. SUPPL. pp. 15-17.
@article{0cb6ecc60c8841f8918c35677c6a0873,
title = "Mechanism of immune response during immunotherapy",
abstract = "Tumor immunology embraces an extensive array of biological phenomena that include interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the center stage because they can be easily demonstrated to specifically recognize autologous cancer cells. However, their role is limited and other components of the immune response are likely necessary for the completion of cancer rejection. Metastatic melanoma and renal cell carcinoma (RCC) are malignancies strongly predisposed to regress in response to the systemic administration of high-dose interleukin (IL)-2. Several clinical Studies in extensive cohorts of patients have shown that this treatment can induce complete or partial clinical regressions of metastatic disease in 15 to 20{\%} of patients who receive this treatment. Although IL-2 has direct pluri-potent effects on cells with immune and inflammatory function, it remains unexplained which cell subset is implicated in mediating tumor regression. In a quest to characterize the mechanism of action of IL-2 during the course of immunotherapy, we have investigated the early changes in transcriptional profiles of circulating mononuclear cells and microenvironment of melanoma metastases following high dose IL-2 administration (720,000 IU/kg) by serial sampling of blood cells and tumors in the form of fine needle aspirate (FNA). Furthermore, studies are currently on-going to characterize the proteomic profiling of RCC patients undergoing the same treatment using protein arrays (manuscript in preparation). The predominant activation of genes related to inflammation and activation of mononuclear phagocytes lead us to further characterize this cell subset in the context of stimulation with a panel of soluble factors potentially present in the circulation and tumor microenvironment.",
keywords = "Immunization, Immunotherapy, Interleukin-2, Melanoma",
author = "Panelli, {Monica C.} and Dirk Nagorsen and Ena Wang and Vladia Monsurro and Ping Jin and Zavaglia Katia and Kina Smith and Yvonne Ngalame and Marincola, {Francesco M.}",
year = "2004",
month = "6",
day = "30",
language = "English",
volume = "45",
pages = "15--17",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "SUPPL.",

}

TY - JOUR

T1 - Mechanism of immune response during immunotherapy

AU - Panelli, Monica C.

AU - Nagorsen, Dirk

AU - Wang, Ena

AU - Monsurro, Vladia

AU - Jin, Ping

AU - Katia, Zavaglia

AU - Smith, Kina

AU - Ngalame, Yvonne

AU - Marincola, Francesco M.

PY - 2004/6/30

Y1 - 2004/6/30

N2 - Tumor immunology embraces an extensive array of biological phenomena that include interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the center stage because they can be easily demonstrated to specifically recognize autologous cancer cells. However, their role is limited and other components of the immune response are likely necessary for the completion of cancer rejection. Metastatic melanoma and renal cell carcinoma (RCC) are malignancies strongly predisposed to regress in response to the systemic administration of high-dose interleukin (IL)-2. Several clinical Studies in extensive cohorts of patients have shown that this treatment can induce complete or partial clinical regressions of metastatic disease in 15 to 20% of patients who receive this treatment. Although IL-2 has direct pluri-potent effects on cells with immune and inflammatory function, it remains unexplained which cell subset is implicated in mediating tumor regression. In a quest to characterize the mechanism of action of IL-2 during the course of immunotherapy, we have investigated the early changes in transcriptional profiles of circulating mononuclear cells and microenvironment of melanoma metastases following high dose IL-2 administration (720,000 IU/kg) by serial sampling of blood cells and tumors in the form of fine needle aspirate (FNA). Furthermore, studies are currently on-going to characterize the proteomic profiling of RCC patients undergoing the same treatment using protein arrays (manuscript in preparation). The predominant activation of genes related to inflammation and activation of mononuclear phagocytes lead us to further characterize this cell subset in the context of stimulation with a panel of soluble factors potentially present in the circulation and tumor microenvironment.

AB - Tumor immunology embraces an extensive array of biological phenomena that include interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the center stage because they can be easily demonstrated to specifically recognize autologous cancer cells. However, their role is limited and other components of the immune response are likely necessary for the completion of cancer rejection. Metastatic melanoma and renal cell carcinoma (RCC) are malignancies strongly predisposed to regress in response to the systemic administration of high-dose interleukin (IL)-2. Several clinical Studies in extensive cohorts of patients have shown that this treatment can induce complete or partial clinical regressions of metastatic disease in 15 to 20% of patients who receive this treatment. Although IL-2 has direct pluri-potent effects on cells with immune and inflammatory function, it remains unexplained which cell subset is implicated in mediating tumor regression. In a quest to characterize the mechanism of action of IL-2 during the course of immunotherapy, we have investigated the early changes in transcriptional profiles of circulating mononuclear cells and microenvironment of melanoma metastases following high dose IL-2 administration (720,000 IU/kg) by serial sampling of blood cells and tumors in the form of fine needle aspirate (FNA). Furthermore, studies are currently on-going to characterize the proteomic profiling of RCC patients undergoing the same treatment using protein arrays (manuscript in preparation). The predominant activation of genes related to inflammation and activation of mononuclear phagocytes lead us to further characterize this cell subset in the context of stimulation with a panel of soluble factors potentially present in the circulation and tumor microenvironment.

KW - Immunization

KW - Immunotherapy

KW - Interleukin-2

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=3543045559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543045559&partnerID=8YFLogxK

M3 - Review article

VL - 45

SP - 15

EP - 17

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - SUPPL.

ER -